Grant: Doctoral: Vanier Canada Graduate Scholarships
University of Toronto
$150,000.00
Evaluating Gene-Gene Interactions for Detection of Risk for Late-Onset Alzheimer's Disease using Established and Novel Neuroimaging Phenotypes
FY 2013-14
Summary
As Canada's population ages, the occurrence of late-onset Alzheimer's disease (AD) is estimated to increase dramatically and pose a dire socio-economic burden. Due to the lack of effective intervention strategies, and recent failures of clinical trials aimed at ameliorating the severity and progression of symptoms, it has become clear that high-risk individuals need to be identified before disease onset so that they can benefit from potential treatments.
Previously, variants within three genes (known at APOE, SORL1, and BDNF) have been associated with changes in the brain that align with the onset of AD. These genes are also mechanistically related at the cellular level. We plan to investigate whether these variants are more predictive of AD risk when considered together (gene-gene interaction), as opposed to independently.
In order to assess gene-gene interactions, we will use neuroimaging data from several hundred elderly individuals who are either healthy or experiencing mild cognitive impairment (MCI) to see if individuals with certain high-risk combinations of genetic variants have greater atrophy in the medial temporal lobe than others. We will use both well-established measures of atrophy (hippocampal volume and cortical thickness) as well more novel metrics that we have developed with collaborators that may improve our ability to predict risk in pre-symptomatic individuals. We will then analyze molecular biomarkers of disease progression (beta-amyloid and phosphorylated tau protein) in cerebrospinal fluid of the same subjects as well as in a separate large postmortem brain sample.
Our study is positioned to make clinical and public health impact by improving our ability to detect people at early risk for AD. If our proposed work is successful, our findings will set the stage for intervention studies in individuals at genetic risk for AD and provide genetic evidence for molecular subtypes of the disease.
Department
Program
Doctoral: Vanier Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
299932
Name
Felsky Daniel
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Evaluating Gene-Gene Interactions for Detection of Risk for Late-Onset Alzheimer's Disease using Established and Novel Neuroimaging Phenotypes
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Epistasis; Genetics; Medial Temporal Lobe; Neuroimaging; Neuropathology; Risk Prediction
Abstract
As Canada's population ages, the occurrence of late-onset Alzheimer's disease (AD) is estimated to increase dramatically and pose a dire socio-economic burden. Due to the lack of effective intervention strategies, and recent failures of clinical trials aimed at ameliorating the severity and progression of symptoms, it has become clear that high-risk individuals need to be identified before disease onset so that they can benefit from potential treatments.
Previously, variants within three genes (known at APOE, SORL1, and BDNF) have been associated with changes in the brain that align with the onset of AD. These genes are also mechanistically related at the cellular level. We plan to investigate whether these variants are more predictive of AD risk when considered together (gene-gene interaction), as opposed to independently.
In order to assess gene-gene interactions, we will use neuroimaging data from several hundred elderly individuals who are either healthy or experiencing mild cognitive impairment (MCI) to see if individuals with certain high-risk combinations of genetic variants have greater atrophy in the medial temporal lobe than others. We will use both well-established measures of atrophy (hippocampal volume and cortical thickness) as well more novel metrics that we have developed with collaborators that may improve our ability to predict risk in pre-symptomatic individuals. We will then analyze molecular biomarkers of disease progression (beta-amyloid and phosphorylated tau protein) in cerebrospinal fluid of the same subjects as well as in a separate large postmortem brain sample.
Our study is positioned to make clinical and public health impact by improving our ability to detect people at early risk for AD. If our proposed work is successful, our findings will set the stage for intervention studies in individuals at genetic risk for AD and provide genetic evidence for molecular subtypes of the disease.
Competitiondate
201311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Felsky, Daniel
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~